Anonymization and Sharing of Individual Patient Data from Clinical Studies

Jason Coarse
UCB Biosciences, Inc.
19.MAY.2016
Agenda

TransCelerate BIOPHARMA INC.
• Overview
• Clinical data transparency workstream

UCB Approach to Data Sharing
• External researcher requests
• Collaborations

AETIONOMY

Final Considerations
• Policy 70 Part 1
• Policy 70 Part 2
• The Future of Sharing
• Lessons Learned
TransCelerate
BIOPHARMA INC.

ACCELERATING THE DEVELOPMENT OF NEW MEDICINES
TransCelerate Today
19+ Organizations and 14 Active Initiatives

2012
10 Founding Members
5 Active Initiatives

2013
17 Member Companies
5 Active Initiatives
1 Exploratory Initiative

2014
17 Member Companies
12 Active Initiatives
1 Exploratory Initiative

Today
19 Member Companies
14 Active Initiatives
2 Ideation Efforts
2 Realized Initiatives
TransCelerate Strategic Priorities

- **Improve the Site Investigator Experience**: Improve the Site Investigator Experience as they work with Sponsors to execute Clinical Trials.
- **Facilitate Information Sharing**: Facilitate the sharing of clinical trial related information as appropriate amongst industry stakeholders, focused on exchanges of information that would enable the industry to capture efficiencies.
- **Enable Harmonization of Clinical Trial Processes**: Enable the industry to move toward greater harmonization of clinical trial processes to facilitate the advancement of technologies and processes within the broader clinical ecosystem.
- **Enhance Sponsor Efficiencies**: Through collaboration, streamline redundant sponsor activities to reduce investigator and Patient burden, while refocusing resources to drive and deliver innovative drugs to patients faster and safely.
- **Improve the Patient Experience**: Improve the Patient Experience by enabling earlier access to well run clinical studies.
Why Protect Privacy?

- It is the right thing to do for patients that participate in clinical trials

Legal requirements such as:

- **HIPAA Privacy Rule**

- **Regulation (EC) No. 45/2001** of the European Parliament and of the Council of 18 December 2000 on the protection of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free movement of such data.

- **Directive 95/46/EC** of the European Parliament and of the Council of October 24, 1995 on the protection of individuals with regards to the processing of personal data and on the free movement of such data.

Ethically important:

- **Declaration of Helsinki**: It is the duty of physicians who are involved in medical research to protect the life, health, dignity, integrity, right to self-determination, privacy, and confidentiality of personal information of research subjects. The responsibility for the protection of research subjects must always rest with the physician or other health care professionals and never with the research subjects, even though they have given consent.
The best way for researchers to test hypotheses is with the use of individual patient level data.

In order to share this data and protect patients’ privacy, the data must be de-identified or anonymized.

TransCelerate has released the “Data De-identification and Anonymization of Individual Patient Data in Clinical Studies – A Model Approach” which describes methods that can be utilized to meet the needs of protecting study participants’ privacy while retaining usable data.

TransCelerate has developed the model approach to assist sponsors in implementing operational methods to protect against disclosure of patients’ personally identifiable information, but the guidance provided by TransCelerate should not be construed as legal advice.

Two methods are described in the approach:

- Enhanced Safe Harbor Method
- Expert Determination Method
Individual Patient Data – Enhanced Safe Harbor

This method incorporates the list of identifiers from HIPAA and Safe Harbor

Determine all of the identifiers in the data

Remove some data that cannot be modified including:

- Free-Text Verbatim Fields
- Sensitive data (illicit drug use or “risky behavior”)
- Rare events (small numerators in a population)
- Date of Birth
- Names of Research Participants
- Contact Information

Recode other pieces of information:

- Patient IDs – change to new set of patient IDs not associated with study documentation
- Event Dates – either use a date offset method or relative day method
Individual Patient Data – Expert Determination

- **Expert Determination** involves “A person with appropriate knowledge of and experience with generally accepted statistical and scientific principles and methods for rending information not individually identifiable:
  - Applying such principles and methods, will help reduce the possibility that the information could be used, alone or in combination with other reasonably available information, by an anticipated recipient to identify an individual who is a subject of the information; and
  - Documents the methods and results of the analysis that justify such determination”

- The TransCelerate model approach recommends using the expert determination method with datasets on rare diseases or small populations that are provided for additional research purposes
Individual Patient Data – Access Requirements

- Regardless of the approach utilized for ensuring privacy of patients when providing individual patient data, some additional protections should be utilized to protect privacy including:
  - Access should be provided to known individuals
  - Access should be provided after receiving a signed data sharing agreement that includes a promise to not try to re-identify patients
  - Access should be provided in a controlled access environment
  - Consideration should be given to how long data will be made available to researchers

- Additionally, for good science, the process of data access requests should include:
  - Publication plan for the results of the analyses
  - Review of research proposal for scientific validity
UCB Approach to Data Sharing
Data Sharing - Examples

- Information UCB proactively shares:
  - Lay summaries on UCB.com
  - CSR synopses on UCB.com
  - Registry reporting on ClinicalTrials.gov, EudraCT, etc.

- Requested data can fall under several different pathways:
  - External requests - via CSDR
  - External collaborations - eg IMI
  - Requests for (new) analyses - ie summary tables or graphs
  - In support of grants
  - Regulatory Agency Interactions - FOIA & EMA Policy 43, and EMA Policy 70

The UCB Data Sharing Process covers each of these categories
Data Sharing with External Researchers

According to UCB Governance, research proposals are managed through CSDR

- UCB stakeholders review proposals for feasibility, IP, CCI etc
- Proposals are then reviewed for scientific merit by an Independent Review Panel

For approved requests:

- Patient-level-datasets are anonymized
- Study documents are redacted: CSR (incl protocol, blank CRF), program specs and aCRF

Deliverables are loaded into a SAS Multi-Sponsor-Environment (MSE)

- The Researcher must sign a Data Sharing Agreement
- Researchers are granted access to the password-protected SAS MSE for an initial 12-month period
- UCB reviews outputs before they can be downloaded; UCB datasets & docs cannot be downloaded
- UCB has courtesy review of the Researcher’s proposed manuscript prior to its submission
Data Sharing with External Researchers
Data Sharing within Collaborations

UCB collaborates with Academia and other Sponsor Companies

As part of collaborations, UCB can provide anonymized patient-level data & redacted study docs

- UCB will only deliver data to suitably secure locations

  - The SAS MSE can be used for collaborations but has limited analysis packages available

  - If the SAS MSE is not deemed suitable for a collaboration, collaborators are to identify an alternative solution that meets required security criteria

- Ideally, anonymization rules are adapted to standardize across all Sponsor companies

  - An IMI project to Analyze and structure different types of data and apply this knowledge to construct a new classification of patient groups based on the underlying causes of disease (AETIONOMY)

  - TransCelerate Placebo Standard of Care – To maximize the value of clinical data collected historically to improve study design, interpret safety signals contextually and improve subject recruitment, by secondary use of pooled control data
An Example Collaboration:
AETIONOMY - Partners

Partners:
UCB, EMC, BI, Fraunhofer, LUH, UKB, ICM, SARD, IDIBAPS, UCL, NeuroRad, PHI, AE, LCSB (UL), KI, Novartis, IDIBAPS, SANOFI, Boehringer, Europe.
AETIONOMY - Sponsor logistics

Concept summary

- Each of the 4 sponsors will submit data to be used in the MSE
  - Further, 3 sponsors will submit data to be used outside of the MSE

Legal considerations

- Each company will have an agreement in place for the data they plan to share
  - Agreements multiply per the number of institutions getting the data
- Sharing in multiple spaces (MSE, TranSmart, etc.) will multiply the complexity
  - More secure environments require fewer rules in the agreement

Documents can be shared separately by company
AETIONOMY - Sponsor logistics

Technology

- MSE can be used to keep the data secure but only allows the use of a few programs
  - Restriction of possible programs may limit possible analyses
    - Other secure areas may be needed to facilitate other analytical programs
  - Less “secure” options require more data manipulation to keep them safe
- Constant consideration of security/utility balance

Data to be shared

- Data should ideally have similar rules across sponsors so that the data can easily be used
- Depending on where the data will be shared, different rules will be applied
AETIONOMY - Knowledge Base

Freely available online  http://aetionomy.scai.fraunhofer.de/

Data, disease modeling and reasoning.

The AETIONOMY concept foresees a primary role of the taxonomy in:

i) describing and organizing the indication-specific data in the data cube, in
ii) linking the data to disease models that are based on causal and correlative relationships and in
iii) support of reasoning over the knowledge that is explicitly represented in related ontologies or knowledge-based disease models.

The consortium has extensive and proven experience in the generation of disease-specific ontologies for NDDs, as demonstrated by the recent publication of the “Alzheimer’s Disease Ontology (ADO)”, and the generation, in collaboration with partners from the pharmaceutical industry, of disease ontologies representing substantial parts of the knowledge on Parkinson’s Disease, Multiple Sclerosis and Epilepsy.

AETIONOMY will not have the resources to validate the entire set of aetiology linked to the taxonomy in the given time and within the budgetary limits. We have therefore carefully designed a validation strategy that will guide the final prospective clinical study meant to demonstrate the validity of the aetiology-based taxonomy. The consortium brings together four leading clinical centres with proven expertise in conducting such sort of studies; addressing effectively the need to validate the mechanism-based taxonomies for both, PD and AD. A dedicated AETIONOMY work package on ethical and legal aspects has a clear European perspective and scope and is set up in a way that reaches out beyond the AETIONOMY project and actively seeks the coordination with other projects funded under the same theme.

AETIONOMY makes extensive use of developments made in and funded by other IMI or EU projects. In the area of knowledge and data management, we build largely on the work done in OpenPHACTS, and we will re-use the entire data curation pipeline developed in the course of eTRIKS. Modelling and mining principles learned from VPH projects will guide our work, leveraging on our involvement in other large EU research initiatives. Finally, the substantial effort made on the side of clinical data integration in the course of EMIF, the European Medical Information Framework, will be accessible to AETIONOMY.
Final Considerations
Current and Future Considerations

New Regulations

- **Policy 0070 – Final Guidance (for Part 1) just released on March 2nd!**
  - Part 1: Post redacted documents publicly – anonymized documents preferred
  - Part 2: Post anonymized documents and anonymized patient level datasets publicly
    - Part 2 is not yet active

- **EU Clinical Trial Regulation 536/2014 requires submission of a summary of results and a lay person summary 1 year after the end of the trial in the EU**
Current and Future Considerations

New Technology

■ How to ‘future-proof’ as new data and new technology become available?
  ■ Wearable devices, phone app integration, new analysis programs, working environments

Collaborations and Beyond

■ Unification of sponsor data in collaborations
■ Synchronization of information in datasets and documents
■ How do we get the most informative data while still keeping patient privacy?
  ■ K-Anonymity
  ■ Blurring
  ■ Other techniques?
Questions?
Thanks!